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Chronic inflammation is an important process leading to tumorigenesis. Therefore, targeting and controlling
inflammation can be a promising cancer therapy. Inflammation is often caused by a variety of inflammatory
cytokine such as the interleukin (IL)-6, a pleiotrophic cytokine known to be involved in the tumorigenesis. In this
study, an in vivo hepatic tumorigenesis model of zebrafish was generated to demonstrate a direct consequence of
the human IL6 expression causing hepatocarcinogenesis. To do this, an elevated expression of the hIL6 gene was
established to specifically target the zebrafish hepatocytes by transgenesis. Interestingly, the elevated hIL6
expression caused the chronic inflammation which results in a massive infiltration of inflammatory cells. This
eventually resulted in the generation of various dysplastic lesions such as clear cell, small cell, and large cell
changes, and also eosinophilic and basophilic foci of hepatocellular alteration. Hepatocellular carcinoma was then
developed in the transgenic zebrafish. Molecular characterization revealed upregulation of the downstream
components involved in the IL6-mediated signaling pathways, especially PI3K/Akt and JAK/STAT3 pathways.
Further investigation indicated that PI3K was the most reactive to the infiltrated inflammatory cells and dysplasia
with large cell change, whereas STAT3 was heavily activated in the region with dysplastic foci, suggesting that the
JAK/STAT3 pathway was mainly implicated in the hepatic tumorigenesis in the current model. Our present study
provides an in vivo evidence of the relationship between chronic inflammation and tumorigenesis and reinforces
the pivotal role of IL6 in the inflammation-associated hepatocarcinogenesis.
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The liver is the largest internal organ and plays a major role in the
systemic metabolism of humans. The organ must not only be able to
produce biochemicals necessary for digestion, it must also be able to
protect against damage by the ingested agents, such as drugs [1].
Hepatic immune system is very important to identify, detoxify, and
also neutralize pathogens, and failure of this immune system can
cause the chronic inflammation which leads to hepatocarcinogenesis.
Chronic inflammation can induce alteration of the specific signaling
pathways involved in cell proliferation and survival during hepatic
regeneration, increasing risk of hepatoceullular carcinogenesis.
Among the various substances present in the inflammation process,
interleukin (IL)-6 has been proven to have a crucial role in
hepatocellular carcinoma (HCC) [2].A
a
a
k
A
S
E
1
S
In
2
R
©
a
b
1
h
Neoplasia Vol. 17, No. 7, 2015 Interleukin-6 induced hepatocellular carcinoma in zebrafish Jung et al. 587IL6 is a highly versatile cytokine which was originally characterized
as the regulator that stimulates the final maturation of B cell [3]. This
cytokine is also known to promote hepatic survival by stimulating
liver regeneration [4–6]. Upon binding of IL6 to its receptor,
glycoprotein 130, the receptor is phosphorylated by Janus kinase
(JAK) and in turn induces multiple signaling pathways, including
JAK/STAT3, PI3K/Akt, and Ras/Raf/MAPK pathways [7]. These
pathways have a fundamental role in the hepatic regeneration by
blocking and reducing apoptotic cascade and oxidative injury [7–9]. A
rapid transition from quiescence into cell cycle of the hepatocytes is thus
a part of the hepatic regeneration process. These suggest that IL6 is an
important mediator of the hepatocyte regeneration and functions as a
critical proregenerative factor and acute-phase inducer in liver injury.
In contrast, growing evidences indicating that IL6 level is elevated
in various cancer tumorigenesis associated with the chronic
inflammation have been reported: Inappropriately high level of the
IL6 production has been detected in breast cancer mammospheres
[10]. A non–small-cell lung adenocarcinoma has also provided
additional evidence for the involvement of IL6 in tumorigenesis [11].
These reports raise the question of whether the elevated cytokine level
is implicated in inflammation and tumorigenesis. In fact, a previous
study showed that a high level of IL6 expression rather inhibits liver
regeneration by increasing expression of the p21, the cyclin-
dependent kinase inhibitor [12]. The results suggest that IL6
possesses both pro- and antimitogenic actions and that its signaling
process might be regulated by a negative feedback loop.
In the past decade, zebrafish has been used as an experimental
model for human diseases, including human liver cancer [13–15].
Zebrafish and humans share the molecular and cellular conservation
at various levels in tumorigenesis, indicating the potential of zebrafish
for modeling human cancer [16]. In the present study, we have
generated and validated a novel transgenic zebrafish model
demonstrating an elevated expression of the human IL6 gene
specifically in the liver. Investigation of the transgenic zebrafish
showed typical features of inflammation-associated dysplasia and
HCC in human. Further characterization at molecular and cellular
levels revealed that the hIL6-induced hepatic tumorigenesis was
mediated by JAK/STAT3 signaling pathway. This report discusses the
in vivo evidence that hepatic expression of the hIL6 induces the
chronic inflammation leading to hepatocarcinogenesis.
Materials and Methods
Transgene Constructs and Transgenesis
All constructs used in our study were sequenced and verified using
the appropriate primers listed in Supplementary Table S1. For
transgenesis, the transgene constructs p(LFABP:Gal4VP16),
p(UAS:RFP), and p(UAS:hIL6,Cmcl2:GFP) were separately gener-
ated (Figure 1A). Briefly, a 2.8-kb upstream region of the
liver-specific LFABP gene was polymerase chain reaction (PCR)–
amplified as referenced by a previous report [17] and used as the
promoter to drive Gal4VP16 gene in the zebrafish liver. The hIL6
cDNA purchased from Open Biosystems (Huntsville, AL) was
PCR-amplified and cloned into the downstream of UAS promoter.
Then, Cmcl2-GFP (for cardiac expression of GFP) was PCR-ampli-
fied and cloned to generate p(UAS:hIL6,Cmcl2:GFP). The
p(UAS:RFP) was prepared by placing the RFP sequence amplified
from pAsRed2 (Invitrogen, Carlsbad, CA) under the pUAS promoter.
Refer to Supplementary Table 1 for primer sequences.For microinjection, each injection mixture was prepared by
reconstituting Tol2-transposase mRNA with the transgene
constructs p(LFABP:Gal4VP16) with p(UAS:RFP) and
p(UAS:hIL6,Cmcl2:GFP) separately in the Danieu’s buffer mixed
with 0.03% phenol red. The injection mixture was then introduced
into the yolk of embryos using an MMPI-2 microinjector at
single-cell stage of AB embryos. F0 founder embryos were selected
under a fluorescence microscope (Olympus, Japan) based on RFP in
the liver and cardiac GFP expression. The zebrafish were bred to give
a birth to the F1 strains Tg(LFABP:Gal4VP16;UAS-RFP) and
Tg(UAS:hIL6,Cmcl2:GFP). By crossing these two Tg strains, the
transgenic zebrafish expressing hIL6 specifically in the liver, i.e.,
Tg(LFABP:Gal4VP16;UAS-RFP;UAS:hIL6,Cmcl2:GFP), was estab-
lished (Figure 1C). We found that all transgenes were transmitted in
normal Mendelian ratio.
Animal Stocks and Embryo Care
All zebrafish were raised in a standardized aquaria system (Genomic
Design Co., Daejeon, Korea) (http://zebrafish.co.kr). The system
provides continuous water flow, biofiltration tank, constant temperature
maintenance at 28.5°C, UV sterilization, and 14-hour light and 10-hour
dark cycle. The genetic strain of the zebrafish used in this studywas theAB
line purchased from Zebrafish International Resource Center (ZIRC,
Eugene, OR) (http://zebrafish.org). Embryos to be processed for
whole-mount analyses were placed in an E3 medium with 0.003%
phenylthiourea at 24 hpf to inhibit pigmentation.We strictly followed the
Guidelines for the Welfare and Use of Animals in Cancer Research [18].
Histology, Immunohistochemistry (IHC), and In Situ
Hybridization (ISH)
Histologic evaluation was done by preparing 4-μm transverse
sections from 4% paraformaldehyde-fixed, paraffin-embedded tissue.
Hematoxylin and eosin (H&E) staining was performed according to the
standard protocol [19]. IHC and ISH experiments were carried out as
previously described [20]. Primary antibodies used in the experiments
were rabbit anti-IL6 (1:200), rabbit anti-caspase 3 (1:100), mouse
anti-proliferating cell nuclear antigen (PCNA) (1:2000), and rabbit
anti-JAK1 (1:200) from Abcam (Cambridge, MA). Mouse anti-
phospho-PI3K (1:100) was purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Rabbit antibodies for phospho-Tuberin/TSC2
(1:200), phospho-mTOR (1:200), phospho-4EBP1 (1:200), phospho-
RS6K (1:200), and phospho-STAT3 (1:200) were purchased from
Cell Signaling (Danvers, MA). For ISH experiment, partial cDNA
sequences were PCR-amplified using the appropriate primers (refer to
Supplementary Table 2) and cloned into pCRII vector (Invitrogen).
Riboprobes were generated using T7 or SP6 digoxigenin labeling kit
(Roche Diagnostics GmbH, Mannheim, Germany). Hybridization was
done at 65°C overnight, and a series of stringent wash was done at 68°C.
Hybridized riboprobes were detected by anti-dig antibody binding and
visualized by incubating with an NBT/BCIP AP substrate solution
(RocheDiagnostics GmbH). Counterstaining was done with neutral red.
Imaging
Olympus MVX10 was used for whole-mount embryo imaging.
Photographs from slide sections were obtained using an Olympus BX51.
Reverse transcriptase (RT)–PCR and Western Blot Analyses
Real-time RT-PCR was performed by using the whole liver tissue
dissected from 3-month-old zebrafish. For each group, RNA sample was
588 Interleukin-6 induced hepatocellular carcinoma in zebrafish Jung et al. Neoplasia Vol. 17, No. 7, 2015extracted by using TRIzol reagent (Invitrogen). cDNA was synthesized
by using aMaxima First Strand cDNA Synthesis Kit (Thermo Scientific
Fermentas, K1641, Glen Burnie, MD). The RT-PCR was performed
by using Maxima SYBR Green/ROX qPCR Master Mix (Thermo
Scientific Fermentas, K0222) on a 7300 Real-Time PCR System(Applied Biosystems, Foster city, CA). Primer sequences for the
RT-RCR are shown in Supplementary Table 3. All experiments were
repeated three times with individually prepared samples. Statistical
significance was analyzed by the Mann-Whitney U test using SPSS 11
software. For Western blot assay, whole cell extracts were prepared from
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sample was separated on a 10% SDS–polyacrylamide gel and transferred
onto a polyvinylidene difluoride membrane (Amersham, GE Health,
Sweden). The membrane was incubated overnight at 4°C with primary
antibody in a PBS blocking solution (nonfat dry milk). Horseradish
peroxidase–conjugated secondary antibody was used for post reaction.
Labeled proteins were then detected by ECL reagents and Hyperfilm
ECL (Amersham Biosciences).
Inhibition Assay on IL6-Mediated Pathway
To block the hIL6-mediated downstream signaling in live
zebrafish, the two STAT3 inhibitors, Niclosamide (S3030; Sell-
eckchem; IC50 0.7 μM) and Stattic (S7024; Selleckchem; IC50 5.1
μM), were used. BKM 120 (sc-364437; Santa Cruz Biotechnology)
was used for inhibiting the downstream molecules of PI3K pathway
(IC50 for p110α, p110β, p110γ, and p110δ with 52 nM, 166 nM,
262 nM, and 116 nM, respectively). To determine treatment doses,
6-week-old juvenile zebrafish were treatedwith a serial escalation of each
inhibitor for 7 days. Maximal tolerable doses (MTDs), i.e., the highest
concentration that caused no more than 25% fatality (100 nM for
BKM120, 0.3 μMforNiclosamide, and 1μMfor Stattic), were used for
the treatment. For short-term treatment, the 6-week-old zebrafish
divided into four groups were treated with the MTDs for 10 days and
then were processed for liver dissection and RT-PCR experiment. For
chemoprevention analyses, the same groups (20 per each group) were
separately treated with each inhibitor in 1-l water tank for 6 weeks and
then were processed for histologic analyses.
Results
Chronic Inflammation Induced by Sustained Expression of
hIL6 in Zebrafish Liver
We have generated transgenic zebrafish lines to demonstrate
hIL6-driven tumorigenesis. To do this, independent transgenic lines
of Tg(UAS:hIL6,Cmcl2:GFP) were established and crossed with
Tg(LFABP:Gal4VP16;UAS:RFP) (Figure 1A). We found that binary
expression by the Gal4-UAS system has allowed the liver specific
expression of the transgenes in the zebrafish (Figure 1, B–D). RFP
expression and ISH analyses confirmed that the transgene expression
was apparently detected in the zebrafish liver from 4 days
postfertilization (dpf) and persisted until adulthood. IHC experiment
against the hIL6 with the liver section also confirmed the hIL6
expression in the hepatocytes (Figure 1C). By selecting the transgenic
lines under a fluorescence microscope, heterozygote zebrafish were
maintained and used for all experiments.Figure 1. Transgenic strategy and specific expression of hIL6 gene
Tol2-mediated transgenesis. (B and C) Embryo images at 4 dpf (left, me
of RFP and cardiac expression of GFPwere used as the indicators to sel
hIL6 (middle) at 4 dpf showed its RNA expression in the liver (black arr
hepatocytes only in Tg(LFABP:Gal4VP16;UAS:RFP;UAS:hIL6,Cmcl2:
liver-specific expression of RFP. Dotted line indicates liver boundary. (E
the hIL6-expressing transgenic fish shows irregular contour due to infl
normal architecture with central vein at the center of image. (H–J) H&E
inflammatory cells in the liver at 6weeks of age. (H) Infiltrationof the infla
red arrowheads, respectively). Feathery degeneration (red arrow) is seen
clear cytoplasm suggests ballooning degeneration of hepatocytes. (J
noted. Spotty necrosis (black arrows) and feathery degeneration (re
inflammation caused enlargement of spleen and adhesion to the liver (in
pancreas, intestine, and testis (inset, control pancreas). Swollen hepat
hepatocytes. (M) Inflammatory cell infiltration in the kidney (inset, con
kidney; I, intestine; L, liver; Ov, Ovary; P, pancreas; SB, swim bladder;We conducted microscopic observations with the liver sections
from the transgenic zebrafish (Figure 1, E–M) and found that the
zebrafish liver appeared to contain various grades of inflammatory cell
infiltration in all of the transgenic zebrafish expressing the hIL6. The
results showed that the inflammatory cell infiltration was often
detectable in portal areas, hepatic sinusoids, and intrahepatic vessels
(Figure 1, H–J). We also found that the inflammatory cell infiltration
occurred in the adjacent organs including pancreas, intestine, spleen,
and kidney (Figure 1, K–M). The inflammatory changes was
classified as low grade or high grade depending on the degree of
inflammatory cell infiltration and organ destruction: Histologically,
low grade shows a predominant infiltration of the inflammatory cells
in the liver with scanty or mild infiltration into the neighboring
organs, still preserving the liver architecture, whereas high grade
shows a massive infiltration of the inflammatory cells into both liver
and its adjacent organs, destructing the organ architecture (Figure 1,
K–M). We found that high grade of the inflammatory change was in
one third (Table 1). We assumed that severe local inflammation in the
liver induced the systemic effect which results in the inflammation in
the hematopoietic and lymphoid organs (kidney and spleen,
respectively). Likely, the severe local inflammation ran off from the
liver into the adjacent organs and caused inflammation in the
pancreas and intestine because of the close proximity between the
liver and these internal organs in zebrafish. Taken together, the results
suggest that the sustained expression of hIL6 has induced chronic
inflammation in the transgenic zebrafish liver.
Hepatocellular Tumorigenesis with Multiple Foci of Dysplasia
Appeared in the hIL6-Expressing Zebrafish Liver
During the course of hepatic tumorigenesis in mouse model,
different types of dysplastic foci have appeared before HCC [22].
Similarly, we found that various hepatocellular changes began to
occur in the transgenic zebrafish liver at 2 months of age, including
clear cell, small and large cell, and eosinophilic and basophilic cell foci
(Figure 2, A–F). Increased cell density and variable degree of cellular
and nuclear pleomorphism were observed. (Figure 2, E–G). Large cell
change with both nuclear pleomorphism and megalocytosis was
notably detected (Figure 2H). Multinucleated cells and the cytoplasm
containing eosinophilic multilamellarlike structures were frequently
found (Figure 2, H and I). We found that most of the dysplastic
foci that occurred in the liver were accompanied by variable degree
of inflammatory changes. Dysplastic foci, however, occasionally
developed in the liver with scanty inflammation of surrounding area
(Figure 2B). Occasionally, the dysplastic foci became larger, forming ain transgenic zebrafish. (A) Structure of the constructs used in the
rged images) showed RFP expression in the liver. Hepatic expression
ect the transgenic embryos under a fluorescencemicroscope. ISH for
owhead). IHC at 6 weeks (right) showing the hIL6 expression at the
GFP). (D) A whole dissected viscera at 3 months showing the
and F) Low-power images at 2 months. Note that the liver surface of
ammation. (G) H&E image of control liver at 6 weeks of age showing
images of the hIL6-expressing zebrafish showing the infiltration of
mmatory cellswas noted at a portal and aperivascular area (black and
. (I) Inflammatory cells at hepatic sinusoids (black arrowhead). Pale to
) Inflammatory cells in an intrahepatic vessel (black arrowhead) are
d arrow) are noted. (K–M) Three-month-old zebrafish. (K) Severe
set, control spleen). (L) Destructive change causing adhesion of liver,
ocytes with pale cytoplasm indicate ballooning degeneration of the
trol kidney showing hematopoietic cells between renal tubules). Ki,
Sp, spleen; T, testis. Bars, 50 μm.
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hepatic tumorigenesis of human (Figure 2Q). The histopathological
analysis revealed that the transgenic zebrafish liver harbors multiple
foci of dysplasia, indicating that the tumorigenic process polyclonally
occurred in multiple areas (Figure 2A). Further investigation revealed
that the dysplastic foci developed in almost all transgenic zebrafish at
3 months, showing near 100% penetrance. In an attempt to count
the number of the dysplastic foci, we prepared serial section slides at
0.5-mm interval for observation of the whole liver. The numbers of
the dysplastic foci were 4.5 ± 1.6, 7.1 ± 2.1, and 6.6 ± 1.9 at 3, 6, and
9 months, respectively (P N .05) (Table 1). Among the dysplastic foci,
clear cell foci were found to be the most predominant as it comprised
52.4%, which is followed by large cell foci (32.1%), small cell foci
(10.9%), eosinophilic cell foci (3.2%), and basophilic cell foci (1.4%)
(Table 1).
We performed IHC experiments for hIL6 to see whether the tumor
cells in the dysplastic focus express the transgene (Figure 2, M–O).
Expression of PCNA as a prognostic indicator [23] to demonstrate
the enhanced cellular proliferation during the liver tumorigenesis was
also investigated (Figure 2, P–R, Supplementary Figure 1). The
results showed that the hepatocytes at the dysplastic foci showed a
higher level of positivity to hIL6 and PCNA expressions, suggesting
that the dysplasia was caused by the direct consequence of the elevated
hIL6 expression. The enhanced cell proliferation often contributed to
form the discrete nodule (Figure 2Q). Eventually, we found that
approximately 12.5% (3/24) and 16.7% (4/24) of the hIL6-
expressing liver contained typical features of HCC at 6 and 9 months
of age, respectively (Table 1). The typical features included severe
nuclear and cytological pleomorphism, prominent nucleoli, and
frequent mitosis in the lesions. Although frank invasion into the
adjacent organs was not found, occasional tumor thrombi were noted
in intrahepatic vessels (Figure 2L). Taken together, the results
suggested that the hIL6-expressing transgenic zebrafish has developed
HCC through the formation of dysplastic foci.
Upregulation of Inflammatory and Carcinogenic Pathways
Driven by the Elevated Expression of hIL6
Understanding the signaling pathway that mediates the inflam-
matory tumorigenesis is important for the identification of novel
therapeutic targets for HCC. Upon binding of IL6 to its receptor, the
pleiotropic effects of IL6 appear through JAK/STAT3 and PI3K/Akt
pathways during hepatic inflammatory tumorigenesis [24–26]. TheseTable 1. Histopathological Changes by hIL6 Expression in Hepatocytes
Tg(LFABP:Gal4VP16;UAS:RFP) Tg(LFABP:Gal4VP16;UAS:RFP;UAS:h
Control (n = 24)
(8 Zebrafish at 3, 6,
and 9 Months)
3 Months (n = 24) 6 M
Hepatic inflammation 1 (3.3%) 100% 100
Low 1 (3.3%) 16 (66.7%) 15
High None 8 (33.3%) 9 (3
Dysplastic foci None 100% n = 108 (4.5 ± 1.6/fish) 100
Clear cell foci 54 (50.0%) 90
Large cell foci 38 (35.2%) 57
Small cell foci 11 (10.2%) 17
Eosinophilic cell foci 3 (2.8%) 6 (3
Basophilic cell foci 2 (1.9%) 3 (1
HCC None 0 (0%) 3 (1
Statistical difference was not found in the number of dysplastic foci or in types according to the monpathways are also implicated in tumor cell survival by regulating
antiapoptotic genes [27]. Another important signaling pathway is
Ras-Raf-MAPK pathway, which also transduces signals for cell
growth, division, and differentiation [28].
To see themolecular regulation induced by the aberrant expression of
hIL6, we selected a list of the genes that might be modulated in the
IL6-mediated pathways and performed RT-PCR experiments (primers
are listed in Supplementary Table 2). The result revealed that the
elevated expression of hIL6 induced upregulation of the various
components involved in the signaling pathways by many folds
(Figure 3). Among these, the most prominent expression change was
detected from c-Myc, known as a cell growth regulator [29] (Figure 3A).
Cell survival and cell cycle regulators MAPK1 and cyclin D1 were also
shown to be upregulated. The results suggest that enhanced
hepatocellular proliferation has been induced by the elevated hIL6
expression. IL1b and IL12a were used as the indicators for
inflammatory response, and the RT-PCR showed that these compo-
nents were also upregulated, suggesting that hepatic inflammation has
been activated in the transgenic zebrafish liver (Figure 3A). Aberrant
activation of the IL6-induced JAK/STAT3 pathways was noticed from
the RT-PCR of their downstream components such as c-Myc, Appa,
Socs, Pim1, and Cis. The activation of PI3K/Akt pathway was also
evident by upregulation of Xiap and Eif1a.
Further confirmation of our findings in the RT-PCR results was
obtained from Western blot experiment (Figure 3B). We found that
the phosphoproteins of the major signaling pathways, pMAPK,
pPI3K, and also pSTAT3, were abundantly present in the transgenic
zebrafish liver, suggesting that the all downstream signaling pathways
of IL6 were activated. Taken together, our results strongly support
that HCC development in the transgenic zebrafish is caused by the
elevated expression of hIL6.
Predominant Activation of JAK/STAT3 Pathway Is Involved
in the IL6-Mediated Tumorigenesis
To find further insights into the molecular mechanism of the
HCC development caused by hIL6, we evaluated the downstream
molecules at histological level by IHC and ISH analyses (Figures 4
and 5, Supplementary Figures 1 and 2). Antibody against active
caspase 3 was frequently reactive to the hepatocytes expressing hIL6,
indicating that the hIL6-mediated chronic inflammation has induced
cell death (Figure 4B). The chronic inflammation inevitably resulted
in the cell damage followed by regenerative cell renewal andIL6,Cmcl2:GFP)
onths (n = 24) 9 Months (n = 24) Sum (n = 72)
% 100% 100%
(62.5%) 17 (70.8%) 48 (66.7%)
7.5%) 7 (29.2%) 24 (33.3%)
% n = 173 (7.2 ± 2.1/fish) 100% n = 158 (6.6 ± 1.9/fish) 100% n = 439 (6.1 ± 1.8/fish)
(52.0%) 86 (54.4%) 230 (52.4%)
(32.9%) 46 (29.1%) 141 (32.1%)
(9.8%) 20 (12.7%) 48 (10.9%)
.5%) 5 (3.2%) 14 (3.2%)
.7%) 1 (0.6%) 6 (1.4%)
2.5%) 4 (16.7%) 8 (8.9%)
th-age of transgenic zebrafish.
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pMAPK, and cyclin D1 was abundantly detected in the liver with
dysplastic and nondysplastic foci, indicating that the regeneration
process has been largely triggered by the elevated IL6 expression in the
liver (Figure 4, D, F, and H). Lineage analyses of the infiltrated
inflammatory cells were performed by ISH with leukocyte markers.
We found that abundant CD4-positive T cells were observed in the
portal tracts with occasional CD8-positive cells at hepatic parenchyma
(Figure 4, J and L). Ighm-positive B cells and Spi1-positive myeloid
cells were also observed at hepatic sinusoids and portal area (Figure 4,N
and P). These findings suggested that the hIL6-induced chronic
inflammation accompanied nonspecific recruitment of the lymphoid
and myeloid lineage cells.
Because both phospho-PI3K and phospho-STAT3, the major
regulators of IL6 signaling pathway, were shown to be activated in the
tumorigenic zebrafish liver (Figure 3), IHC was performed to further
delineate the inflammation-induced tumorigenesis at the histologic level
(Figure 5). Interestingly, we found that pPI3K expression was largely
restricted to the infiltrated inflammatory cells but not to the dysplastic
foci (Figure 5A and Supplementary Figure 2). Among the various
dysplastic foci, only the cells with large cell change were prominently
reactive to the pPI3K immunostaining (Figure 5B and Supplementary
Figure 2). Similarly, the downstream components of PI3K such as pAkt1,
pRS6K, pTuberin, and p4EBP1 were shown to be positive to the
hepatocytes with large cell change but not to the other dysplastic and
HCC cell (Figure 5,C–F). The IHC experiment using the serial sections
of the zebrafish liver with large cell change also showed a predominant
activation of the molecular components in the PI3K pathway
(Supplementary Figure 2). The results suggest that the PI3K/Akt
pathway is themost reactive to the inflammatory cell and large cell change
and is not primarily involved in the IL6-induced tumorigenesis.
Hepatocellular immunostaining to identify pSTAT3 was also
done (Figure 5 and Supplementary Figure 1). The result showed that
virtually all of the hepatocytes expressing hIL6 were reactive to
pSTAT3 and that the pSTAT3 expression heavily occurred in the
region with dysplastic foci (Figure 5, G–I and Supplementary Figure
1). Unlike the pPI3K expression, however, we found that the
infiltrated inflammatory cells were negative to the pSTAT3 staining
(Figure 5, G–I). ISH experiments for the downstream molecules of
JAK/STAT3 signaling pathway such as Socs, Appa, Cis, and Pim1
revealed that the genes were strongly expressed in the dysplastic
region which was reactive to pSTAT3 immunostaining (Figure 5,
J–O). Expression analysis with serial sections of the zebrafish liver
corroborated the enhanced activation of STAT3 pathway (Supple-
mentary Figure 1). Taken together, our results suggest that activation
of JAK/STAT3 pathway in hepatocytes is primarily responsible for
IL6-mediated hepatic tumorigenesis.Drug Inhibition of the IL6-Mediated Signaling Pathways
Our molecular and cellular analyses indicated that the IL6-mediated
JAK/STAT3 pathway was a key signal transduction pathway implicated
in the hepatic tumorigenesis. Evaluation of inhibition efficacy of the JAK/
STAT3 pathway would further reveal that the signaling pathway is
mainly responsible for the tumor development. Inhibition assay of the
PI3K/Akt pathway would also support that the pathway is involved in
the IL6-mediated hepatic inflammation. To elucidate, two STAT3
inhibitors (Niclosamide and Stattic) and a PI3K inhibitor (BKM120)
were administered to the transgenic zebrafish, and their downstreamcomponents were investigated at themolecular and cellular level (Figure 6).
Real-time RT-PCR performed after 10 days with the inhibitor treatment
indicated that Niclosamide and Stattic showed modest inhibition of JAK/
STAT3 pathway, whereas BKM120 was not effectively reactive to the
PI3K inhibition (Figure 6A). The results suggested that the drug inhibition
partially worked in the JAK/STAT3 pathway.
Histologic evaluation was also performed by H&E and IHC after
6 weeks of the treatment, a long-term treatment. We found that
BKM120 showed the decreased immunoreactivity to pPI3K in the
inflammatory cells (Figure 6B), supporting our present finding of the
PI3K/Akt pathway which is involved more likely in the inflammatory
process. The STAT3 inhibitors revealed variable effect on the
expression of downstream genes, i.e., decreased expression was noted
for Appa but others on ISH (Figure 6F). Likely, the pSTAT3 or
PCNA immunoreactivity in the hepatocytes was not inhibited by
either Nicolsamide or Stattic, suggesting that the inhibitors did not
completely suppress the JAK/STAT3 pathway (Figure 6, C and D).
Nonetheless, identification of the PCNA positivity correlated with
the pSTAT3 expression at the same tissue section (Figure 6, B–D, red
circles), suggesting that activation of the JAK/STAT3 pathway is
responsible for IL6-mediated tumorigenesis.
Likely, the counted numbers of the dysplastic foci were 3.3 ± 1.1,
2.7 ± 0.9, 3.1 ± 1.0, and 3.0 ± 1.1 in control, BKM120, Nicolsamide,
and Stattic treatment groups, respectively (P N .05). This seemed to
be caused by dose-limiting toxicity of the inhibitors: We found a
treatment toleration with BKM120 at the concentration of 100 nM
(comparable to the concentration of IC50), whereas the zebrafish
were poorly tolerable to Nicolsamide (MTD 0.3 μM, which is lower
than IC50 of 0.7 μM) and Stattic (MTD 1 μM, which is lower than
IC50 of 5.1 μM).
Discussion
In the present study, we have introduced the hIL6 gene into zebrafish
to investigate if the elevated hIL6 expression causes hepatocellular
tumorigenesis in the liver. IL6 is a well-known cytokine playing a
crucial role in liver regeneration and also hepatic tumorigenesis
depending on its expression condition [4–6,11]. Under normal
circumstances, the inflammation-associated expression of IL6 might
have a protective role of hepatocyte death. Inappropriate or
uncontrolled expression of this pleiotrophic cytokine, however, can
be detrimental to the liver, causing accentuation of inflammatory
process, cell damage and death, and eventually generation of HCC. In
our study, we observed that the zebrafish containing the elevated
expression of hIL6 gene specifically in the liver caused the chronic
inflammation which results in a massive infiltration of inflammatory
cells (Figure 1). Detailed microscopic investigation of the liver
showed that the transgenic zebrafish liver developed typical features of
HCC with dysplastic foci, suggesting that the elevated expression of
hIL6 caused hepatocellular tumorigenesis (Figure 2).
IL6 acts through multiple signal transduction pathways [4,8,10].
Among the pathways, JAK/STAT3 plays very important roles in
inflammation and tumorigenesis. STAT3 belongs to the STAT
protein family consisting of seven members and is especially known to
be a key element in tumor initiation and progression [30,24]. Normal
activation of the STAT3 by phosphorylation in response to IL6 leads
to turn on transcriptions of many downstream genes involved in
normal hepatic development, whereas abnormal persistent activation
of the element contributes to tumorigenesis and chronic inflamma-
tion, suggesting that STAT3 has dual role. In our study with the
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activate the JAK/STAT3 pathway, causing tumorigenesis. To
delineate the IL6-driven hepatic inflammation and tumorigenesis,
we took advantage of using different downstream markers to take
insights into the molecular mechanism. Interestingly, we found that
virtually all neoplastic hepatocytes are strongly reactive to STAT3
elements (Figure 5). Identification of the phospho-STAT3 protein
and its downstream molecules was prominently localized in the
hepatic region with dysplastic foci. The results indicated that the
JAK/STAT3 pathway activated by hIL6 expression is primarily
implicated in the hepatocellular tumorigenesis.PI3K, another regulatory element in the IL6-mediated signaling,
showed the most reactivity to the infiltrated inflammatory cells, and
the reactivity of its downstream molecules appeared mainly on the
hepatocytes with large cell change (Figure 5 and Supplementary
Figure 2). Although the IL6-mediated activation of PI3K/Akt
pathway may play an important role in the dysplasia with large cell
changes, our findings suggested that the PI3K/Akt pathway was
rather interconnected with the inflammatory process than with
tumorigenesis during the IL6-mediated signaling.
Another IL6-mediated signaling is Ras/Raf/MAPK pathway [29].
In this pathway, the mitogen-activated protein kinase, pMAPK, plays
Figure 3. RT-PCR and Western blot analysis. Samples were prepared from the whole livers dissected under a fluorescence microscopy
from 3-month-old zebrafish. (A) Real-time RT-PCR showing differential expression of the downstream components of IL6 signaling.
Graphs are shown with mean value and standard error bars. Note the prominent upregulation of Myca and JAK/STAT3 downstream
components. (B) Western blot hybridization showing upregulation of the active phosphorylated downstream components of IL6 signaling
pathway. C, Tg(LFABP:Gal4VP16;UAS:RFP). hIL6, Tg(LFABP:Gal4VP16;UAS:RFP;UAS:hIL6,Cmcl2:GFP). The asterisk indicates significant
difference between the hIL6-expressing group and control as determined by Mann-Whitney U test (P b .05). hIL6, 26 kDa; MAPK1, 52
kDa; pMAPK1, 52 kDa; caspase 3a, 35 kDa; pPI3K, 85 kDa; pSTAT3, 86 kDa; β-actin, 45 kDa.
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transducing extracellular signal to the cell nucleus, and thereby its
specific genes are activated for cell growth [26]. In our RT-PCR
experiment, various cellular proliferation markers were shown to be
upregulated in the hIL6-expressing zebrafish liver (Figure 3).
Immunostaining analysis revealed that their upregulations appeared
on the hepatocytes with both dysplastic and also nondysplastic foci
(Figure 4). The results indicated that the hepatocellular proliferation
and regeneration process has been largely triggered by the elevated
IL6 expression in the transgenic zebrafish liver. Taken together, our
study revealed that the elevated IL6 expression induced inflammation
and tumorigenesis and that the IL6-induced HCC was mediated
mainly by JAK/STAT3 pathway.Figure 2. H&E staining of liver tumor progression in the transgenic zeb
zebrafish. (J–L) Six-month-old zebrafish. (M) and (P) are control live
Tg(LFABP:Gal4VP16;UAS:RFP;UAS:hIL6,Cmcl2:GFP). All red arrowh
alteration (red arrowheads). Clear cell change was most frequently
surrounding liver. (C) A high-power observation of the boxed area
hepatocellular alteration. (E) Basophilic cell change showing cytologi
ratio. (F) Small cell change with increased cell density and high
pleomorphism and occasional multinucleation (black arrowheads).
multinucleated cells (black arrowheads). (I) Dysplastic changes with
HCCs showingmarked nuclear and cytological pleomorphism of tumo
boxed area of inset. Occasional mitoses are seen (black arrowheads
tumor thrombi (red arrowhead in L). (M–O) IHC against hIL6. Contrary
highly express hIL6. (O) Hepatocytes in a dysplastic focus (red arrowh
(P) Control. (Q) PCNA expression was highly positive in the cells in the
(R) The hepatocytes at dysplastic focus (red arrowheads) showed
nondysplastic area (black arrowhead). Bars, 50 μm.It seems that IL6 plays a role in two different ways to cause
hepatocarcinogenesis: First is the robust chronic inflammation which
results in the infiltration of inflammatory cells. The chronic
inflammation induces cell damage followed by the enhanced
proliferation which results in the occurrence of dysplasia. Secondly,
the activated JAK/STAT3 pathway itself may be sufficient enough to
induce dysplasia because our findings showed that dysplastic foci still
occurred in the liver with scanty inflammation in the surrounding area.
In zebrafish, several inducible models showing the features of
hepatocarcinogenesis have been reported [31–36]. Induced expression
of oncogenic xmrk gene showed a successful HCC in zebrafish [31].
Liver tumors were rapidly induced with 100% penetrance in both
juvenile and adult xmrk transgenic fish. The authors also examinedrafish. (A–C) Two-month-old zebrafish. (D–I, M–R) Three-month-old
r images of Tg(LFABP:Gal4VP16; UAS:RFP), and others are from
eads indicate dysplastic foci. (A) Multiple foci of hepatocellular
observed. (B) Clear cell focus with scanty inflammation in the
of (B) showing nuclear pleomorphism. (D) Eosinophilic focus of
cal atypia with nuclear pleomorphism and high nucleocytoplasmic
nucleocytoplasmic ratio. (G) Small cell change showing nuclear
(H) Large cell change with nuclear pleomorphism and frequent
eosinophilic mutilamellar structure (black arrowhead). (J–L) Overt
r cells at 6 (J) and 9 (K and L) months. (J) High-magnification view of
). Occasionally, tumor cells invaded intrahepatic vessels, forming
to control liver (M), majority of the hepatocytes in M were found to
ead) showing a robust expression of hIL6. (P–R) IHC against PCNA.
dysplastic nodule which appears as bulging mass (red arrowheads).
more frequent positivity to PCNA expression than the ones at
Figure 4. hIL6-induced chronic inflammation, cell death, and enhanced proliferation. All images were obtained from 3-month-old
zebrafish. (A, C, E, G, I, K, M, and O) Controls. (B) IHC against active caspase 3a showing the positive hepatocytes in the hIL6-expressing
liver. (D, F, and H) IHC against proliferation markers PCNA, pMAPK, and cyclin D1, respectively. Note that even the hIL6-expressing liver
with nondysplastic foci (D and H) showed marked increase of the marker expression. A dysplastic focus in (F) (red arrowheads) shows a
robust positivity for pMAPK. (I–P) ISH for leukocyte markers CD4, CD8a, Ighm, and Spi1. Insets in (M) and (O) indicate zebrafish spleen
used as internal control. Majority of the infiltrated T cells are CD4-positive helper T cells. The infiltrated inflammatory cells are located at
the portal tract, sinusoids, and intrahepatic vessels. Bars, 50 μm.
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observed no obvious changes. A very recent report with the liver specific
expression of oncogenic kras gene in zebrafish also showed in vivo
hepatocarcinogenesis and progression [35]. Expression of the kras gene
favored a proinflammatorymicroenvironmentwhich results in the rapid
recruitment of neutrophils to oncogenic liver, stimulating HCC. In the
present study, our zebrafish model clearly showed the correlation
between the chronic inflammation and the occurrence of dysplasia and
HCC, which differs from the previous studies. Furthermore, the
progression of chronic inflammation and carcinogenesis reflects most of
the cellular architectures of the human HCC associated with chronic
hepatitis B or C viral infection.
In summary, our study showed that the human IL6 expressed
unstably but specifically in the zebrafish liver demonstrated the
progression of chronic inflammation and hepatocarcinogenesis. Con-
sidering that most of the human HCCs occur through virus-associated
chronic inflammation/dysplasia/carcinoma, our current zebrafish model
mimics the carcinogenic process occurring in human liver. Further study
with the zebrafish model will take more insight into the molecular
mechanism of the inflammation-associated hepatocarcinogenesis.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.07.005.
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